James “Jed” Ferguson III, MD, PhD, of the University of Alabama at Birmingham, highlights some of the interesting bladder cancer data presented at the 2024 Southeastern Section of the AUA meeting, including a phase 1 analysis of intravesical erdafitinib (TAR-210) in patients with NMIBC whose tumors harbor select FGFR alterations, as well as the results from SUNRISE-1, an analysis of intravesical gemcitabine (TAR-200) alone, in combination with cetrelimab, or cetrelimab alone in patients with BCG-unresponsive, high-risk NMIBC.
Негізгі бет SESAUA 2024: TAR-210, 200 for NMIBC
Пікірлер: 1